Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
107Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $27.48M | $-7.72M | $-0.47 |
| 2024 | $41.81M | $6.65M | $0.41 |
| 2023 | $24.41M | $485.0K | $0.03 |
| 2022 | $44.53M | $24.24M | $1.47 |
| 2021 | $27.04M | $4.12M | $0.25 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.09 per share
Typical surprise -245.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.53 vs $-0.13miss
- Thu, May 7$-0.16 vs $-0.13miss
- Thu, Feb 12$-0.19 vs $-0.06miss
- Thu, Nov 6$-0.06 vs $-0.11beat
- Thu, Aug 7$-0.06 vs $0.01miss
- Thu, May 15$-0.16 vs $0.04miss
Estimates and results for SRTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
SRTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (3)
- Newsmarketbeat.com·1d ago·Neutral
Sensus Healthcare Q2 Earnings Call Highlights Sensus Healthcare NASDAQ: SRTS reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June.
View source ↗ - Newsseekingalpha.com·1d ago·Positive
Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsbusinesswire.com·1d ago·Neutral
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease …
View source ↗
